Bernard Doger

1.8k total citations
61 papers, 535 citations indexed

About

Bernard Doger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bernard Doger has authored 61 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Bernard Doger's work include Cancer Immunotherapy and Biomarkers (21 papers), Lung Cancer Treatments and Mutations (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Bernard Doger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Lung Cancer Treatments and Mutations (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Bernard Doger collaborates with scholars based in Spain, United States and United Kingdom. Bernard Doger's co-authors include Víctor Moreno, Emiliano Calvo, Martin Förster, Frédéric Triebel, Maria J. de Miguel, Matthew Krebs, Julio A. Peguero, Enriqueta Felip, Enric Carcereny and Irene Braña and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Bernard Doger

56 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bernard Doger Spain	13	349	132	125	123	70	61	535
Zhitao Ying China	14	502 1.4×	171 1.3×	171 1.4×	48 0.4×	37 0.5×	73	797
Dominic W. Lai United States	12	150 0.4×	87 0.7×	78 0.6×	114 0.9×	85 1.2×	24	433
Paola Simona Ravenda Italy	12	324 0.9×	118 0.9×	275 2.2×	158 1.3×	165 2.4×	16	737
Cyrus Sayehli Germany	14	499 1.4×	218 1.7×	245 2.0×	87 0.7×	81 1.2×	37	831
Anne Beaven United States	19	511 1.5×	186 1.4×	209 1.7×	121 1.0×	24 0.3×	89	956
N. Nora Bennani United States	17	440 1.3×	123 0.9×	167 1.3×	51 0.4×	71 1.0×	96	947
Bihui Cao China	9	272 0.8×	107 0.8×	222 1.8×	110 0.9×	35 0.5×	19	536
Chad A. Hamilton United States	11	290 0.8×	214 1.6×	142 1.1×	94 0.8×	117 1.7×	26	1.0k
Chakradhar Yakkala Switzerland	8	162 0.5×	117 0.9×	292 2.3×	90 0.7×	31 0.4×	10	517
Almudena García‐Castaño Spain	11	204 0.6×	193 1.5×	68 0.5×	188 1.5×	76 1.1×	30	496

Countries citing papers authored by Bernard Doger

Since Specialization

Citations

This map shows the geographic impact of Bernard Doger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Doger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Doger more than expected).

Fields of papers citing papers by Bernard Doger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Doger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Doger. The network helps show where Bernard Doger may publish in the future.

Co-authorship network of co-authors of Bernard Doger

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Doger. A scholar is included among the top collaborators of Bernard Doger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Doger. Bernard Doger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Doger, Bernard, Jeffrey Yachnin, Irene Moreno, et al.. (2025). 581 Preliminary phase 1 results of clinical trial investigating BI-1910, a tumor necrosis factor receptor 2 (TNFR2) agonist, in solid tumor cancer patients. Regular and Young Investigator Award Abstracts. A660–A661.

Majem, Margarita, Enric Carcereny, Bernard Doger, et al.. (2025). Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study.

Calvo, Emiliano, Bernard Doger, Joan Carles, et al.. (2025). A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. The Oncologist. 30(1). 2 indexed citations

Doger, Bernard, Daniel Morillo, Balázs Győrffy, et al.. (2025). Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat. npj Precision Oncology. 9(1). 331–331. 1 indexed citations

Rullan, Antonio, Víctor Moreno, Bernard Doger, et al.. (2024). Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives. Cancer Treatment Reviews. 127. 102746–102746. 6 indexed citations

Förster, Martin, Irene Braña, Antonio López–Pousa, et al.. (2024). Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 30(17). 3726–3734. 8 indexed citations

Moreno, Irene, Cristina Nieto‐Jiménez, Bernard Doger, et al.. (2024). Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2. International Journal of Molecular Sciences. 25(4). 2222–2222. 3 indexed citations

Tourneau, C. Le, Zoltán Takácsi‐Nagy, Laetitia Finzi, et al.. (2023). Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I Trial. International Journal of Radiation Oncology*Biology*Physics. 117(2). S99–S99. 1 indexed citations

Doger, Bernard, Cristina Nieto‐Jiménez, Víctor Moreno, et al.. (2023). Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities. Cancers. 15(12). 3250–3250. 1 indexed citations

10.

Ramos‐Fransí, Alba, et al.. (2022). Anti-drug antibodies in the current management of cancer. Cancer Chemotherapy and Pharmacology. 89(5). 577–584. 11 indexed citations

11.

Olmedo, M.E., Martin Förster, Víctor Moreno, et al.. (2021). Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Investigational New Drugs. 39(5). 1275–1283. 14 indexed citations

12.

Hoffmann, Caroline, Valentin Calugaru, Édith Borcoman, et al.. (2021). Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. European Journal of Cancer. 146. 135–144. 45 indexed citations

13.

Moreno, Víctor, et al.. (2021). Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond. Current Opinion in Pharmacology. 59. 70–84. 18 indexed citations

14.

Miguel, Maria J. de, Bernard Doger, Valentina Boni, et al.. (2020). Increased vulnerability of clinical research units during the COVID‐19 crisis and their protection. Cancer. 126(17). 3907–3911. 10 indexed citations

15.

Majem, Margarita, Enriqueta Felip, Bernard Doger, et al.. (2020). 1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma. Annals of Oncology. 31. S818–S818. 4 indexed citations

16.

Moreno, Víctor, Irene Braña, Juan Manuel Sepúlveda-Sánchez, et al.. (2020). 527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study. Annals of Oncology. 31. S463–S464. 1 indexed citations

17.

Förster, Martin, Enriqueta Felip, Bernard Doger, et al.. (2020). 927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients. Annals of Oncology. 31. S667–S667. 7 indexed citations

18.

Dicker, Adam P., Thierry de Baère, Caroline Hoffmann, et al.. (2019). Hafnium Oxide Nanoparticles Activated By Radiotherapy: Potential for Local Treatment of a Wide Variety of Solid Tumors. International Journal of Radiation Oncology*Biology*Physics. 105(1). S241–S241. 1 indexed citations

19.

Doger, Bernard, et al.. (2019). Cemiplimab for the treatment of advanced cutaneous squamous cellcarcinoma. Drugs of today. 55(8). 485–485. 6 indexed citations

20.

Saurí, Tamara, Ahmad Awada, Emiliano Calvo, et al.. (2016). Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer. Annals of Oncology. 27. vi125–vi125. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact